Effect of probiotics on respiratory, gastrointestinal and nutritional outcomes in patients with cystic fibrosis: A systematic review

Journal of Cystic Fibrosis

Volumn 16, Issue 2, 2017, Pages 186-197

  Anderson, Jacqueline L ^a   Miles, Caitlin ^b   Tierney, Audrey C ^a,c  

^a LA TROBE UNIVERSITY   (Australia)

^b SOUTHERN HEALTH   (Australia)

^c Prahran ^*  (Australia)

Author keywords

Cystic fibrosis; Probiotics; Systematic review

Indexed keywords

PANCREAS ENZYME; PROBIOTIC AGENT;

COMORBIDITY; CYSTIC FIBROSIS; FORCED EXPIRATORY VOLUME; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TRACT FUNCTION; HOSPITAL ADMISSION; HUMAN; INTENTION TO TREAT ANALYSIS; INTESTINE FLORA; META ANALYSIS; METHODOLOGY; NUTRITION; OUTCOME ASSESSMENT; QUALITY OF LIFE; RESPIRATORY FUNCTION; REVIEW; SYSTEMATIC REVIEW; CLASSIFICATION; COMPLICATION; GASTROINTESTINAL DISEASE; RESPIRATORY TRACT DISEASE; TREATMENT OUTCOME;

CYSTIC FIBROSIS; GASTROINTESTINAL DISEASES; HUMANS; PROBIOTICS; RESPIRATORY TRACT DISEASES; TREATMENT OUTCOME;

EID: 85000799140     PISSN: 15691993     EISSN: 18735010     Source Type: Journal    
DOI: 10.1016/j.jcf.2016.09.004     Document Type: Review

References (35)

1. [1] Li, L., Somerset, S., The clinical significance of the gut microbiota in cystic fibrosis and the potential for dietary therapies. Clin Nutr 33 (2014), 571–580.
2. [2] Rogers, G.B., Carroll, M.P., Hoffman, L.R., Walker, A.W., Fine, D.A., Bruce, K.D., Comparing the microbiota of the cystic fibrosis lung and human gut. Gut Microbes 1 (2010), 85–93.
3. [3] De Lisle, R.C., Borowitz, D., The cystic fibrosis intestine. Cold Spring Harb Perspect Med, 3, 2013, a009753.
4. [4] Bodewes, F.A., Verkade, H.J., Taminiau, J.A., Borowitz, D., Wilschanski, M., Cystic fibrosis and the role of gastrointestinal outcome measures in the new era of therapeutic CFTR modulation. J Cyst Fibros 14 (2015), 169–177.
5. [5] Quigley, E.M., Gut bacteria in health and disease. Gastroenterol Hepatol 9 (2013), 560–569.
6. [6] Whelan, K., Quigley, E.M., Probiotics in the management of irritable bowel syndrome and inflammatory bowel disease. Curr Opin Gastroenterol 29 (2013), 184–189.
7. [7] Gollwitzer, E.S., Marsland, B.J., Microbiota abnormalities in inflammatory airway diseases—potential for therapy. Pharmacol Ther 141 (2014), 32–39.
8. [8] Ooi, C.Y., Durie, P.R., Cystic fibrosis from the gastroenterologist's perspective. Nat Rev Gastroenterol Hepatol, 2016.
9. [9] Food and Agriculture Organisation of the United Nations and WHO Working Group, Guidelines for the evaluation of probiotics in food. 2002, FAO/WHO, Geneva, Switzerland.
10. [10] Nagalingam, N.A., Cope, E.K., Lynch, S.V., Probiotic strategies for treatment of respiratory diseases. Trends Microbiol 21 (2013), 485–492.
11. [11] Goldenberg, J.Z., Ma, S.S., Saxton, J.D., Martzen, M.R., Vandvik, P.O., Thorlund, K., et al. Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children. Cochrane Database Syst Rev, 5, 2013, Cd006095.
12. [12] Madan, J.C., Koestler, D.C., Stanton, B.A., Davidson, L., Moulton, L.A., Housman, M.L., et al. Serial analysis of the gut and respiratory microbiome in cystic fibrosis in infancy: interaction between intestinal and respiratory tracts and impact of nutritional exposures. mBio, 3, 2012.
13. [13] Higgins, J.P.T., Green, S., (eds.) Cochrane handbook for systematic reviews of interventions version 5.1.0 [updated March 2011], 2011, The Cochrane Collaboration.
14. [14] Liberati, A., Altman, D.G., Tetzlaff, J., Mulrow, C., Gotzsche, P.C., Ioannidis, J.P., et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol 62 (2009), e1–34.
15. [15] Downs, S.H., Black, N., The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J Epidemiol Community Health 52 (1998), 377–384.
16. [16] Infante Pina, D., Redecillas Ferreiro, S., Torrent Vernetta, A., Segarra Canton, O., Maldonado Smith, M., Gartner Tizziano, L., et al. Improvement of intestinal function in cystic fibrosis patients using probiotics. An Pediatr (Barc) 69 (2008), 501–505.
17. [17] Bruzzese, E., Callegari, M.L., Raia, V., Viscovo, S., Scotto, R., Ferrari, S., et al. Disrupted intestinal microbiota and intestinal inflammation in children with cystic fibrosis and its restoration with Lactobacillus GG: a randomised clinical trial. PLoS One, 9, 2014, e87796 [Electronic Resource].
18. [18] Di Nardo, G., Oliva, S., Menichella, A., Pistelli, R., De Biase, R.V., Patriarchi, F., et al. Lactobacillus reuteri ATCC55730 in cystic fibrosis. J Pediatr Gastroenterol Nutr 58 (2014), 81–86.
19. [19] Fallahi, G., Motamed, F., Yousefi, A., Shafieyoun, A., Najafi, M., Khodadad, A., et al. The effect of probiotics on fecal calprotectin in patients with cystic fibrosis. Turk J Pediatr 55 (2013), 475–478.
20. [20] Jafari, S.A., Mehdizadeh-Hakkak, A., Kianifar, H.R., Hebrani, P., Ahanchian, H., Abbasnejad, E., Effects of probiotics on quality of life in children with cystic fibrosis; a randomized controlled trial. Iran J Pediatr 23 (2013), 669–674.
21. [21] del Campo, R., Garriga, M., Perez-Aragon, A., Guallarte, P., Lamas, A., Maiz, L., et al. Improvement of digestive health and reduction in proteobacterial populations in the gut microbiota of cystic fibrosis patients using a Lactobacillus reuteri probiotic preparation: a double blind prospective study. J Cyst Fibros 13 (2014), 716–722.
22. [22] Bruzzese, E., Raia, V., Spagnuolo, M.I., Volpicelli, M., De Marco, G., Maiuri, L., et al. Effect of Lactobacillus GG supplementation on pulmonary exacerbations in patients with cystic fibrosis: a pilot study. Clin Nutr 26 (2007), 322–328.
23. [23] Weiss, B., Bujanover, Y., Yahav, Y., Vilozni, D., Fireman, E., Efrati, O., Probiotic supplementation affects pulmonary exacerbations in patients with cystic fibrosis: a pilot study. Pediatr Pulmonol 45 (2010), 536–540.
24. [24] Bruzzese, E., Raia, V., Gaudiello, G., Polito, G., Buccigrossi, V., Formicola, V., et al. Intestinal inflammation is a frequent feature of cystic fibrosis and is reduced by probiotic administration. Aliment Pharmacol Ther 20 (2004), 813–819.
25. [25] Wainwright, C.E., Elborn, J.S., Ramsey, B.W., Marigowda, G., Huang, X., Cipolli, M., et al. Lumacaftor-Ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR. N Engl J Med 373 (2015), 220–231.
26. [26] King, S., Glanville, J., Sanders, M.E., Fitzgerald, A., Varley, D., Effectiveness of probiotics on the duration of illness in healthy children and adults who develop common acute respiratory infectious conditions: a systematic review and meta-analysis. Br J Nutr 112 (2014), 41–54.
27. [27] Heltshe, S.L., Goss, C.H., Thompson, V., Sagel, S.D., Sanders, D.B., Marshall, B.C., et al. Short-term and long-term response to pulmonary exacerbation treatment in cystic fibrosis. Thorax, 2015.
28. [28] Ford, A.C., Quigley, E.M., Lacy, B.E., Lembo, A.J., Saito, Y.A., Schiller, L.R., et al. Efficacy of prebiotics, probiotics, and synbiotics in irritable bowel syndrome and chronic idiopathic constipation: systematic review and meta-analysis. Am J Gastroenterol 109 (2014), 1547–1561 [quiz 6, 62].
29. [29] Marsland, B.J., Trompette, A., Gollwitzer, E.S., The gut-lung axis in respiratory disease. Ann Am Thorac Soc 12:Suppl. 2 (2015), S150–S156.
30. [30] Koning, C.J., Jonkers, D., Smidt, H., Rombouts, F., Pennings, H.J., Wouters, E., et al. The effect of a multispecies probiotic on the composition of the faecal microbiota and bowel habits in chronic obstructive pulmonary disease patients treated with antibiotics. Br J Nutr 103 (2010), 1452–1460.
31. [31] Konstan, M.W., Plant, B.J., Elborn, J.S., Rodriguez, S., Munck, A., Ahrens, R., et al. Efficacy response in CF patients treated with ivacaftor: post-hoc analysis. Pediatr Pulmonol 50 (2015), 447–455.
32. [32] Hempel, S., Newberry, S., Ruelaz, A., Wang, Z., Miles, J.N., Suttorp, M.J., et al. Safety of probiotics used to reduce risk and prevent or treat disease. Evid Rep Technol Assess, 1-645, 2011.
33. [33] Van den Nieuwboer, M., Brummer, R.J., Guarner, F., Morelli, L., Cabana, M., Claasen, E., The administration of probiotics and synbiotics in immune compromised adults: is it safe?. Benefic Microbes 6 (2015), 3–17.
34. [34] Abbott, J., Hart, A., Havermans, T., Matossian, A., Goldbeck, L., Barreto, C., et al. Measuring health-related quality of life in clinical trials in cystic fibrosis. J Cyst Fibros 10:Suppl. 2 (2011), S82–S85.
35. [35] Whelan, K., Editorial: the importance of systematic reviews and meta-analyses of probiotics and prebiotics. Am J Gastroenterol 109 (2014), 1563–1565.